Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

NCT05565417 is registered in ClinicalTrials.gov with Immunitas Therapeutics as lead sponsor.

NCT NCT05565417
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05565417 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Lead sponsor
Immunitas Therapeutics
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
November 28, 2022
Completion date
January 31, 2026
Enrollment
67 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

burkitt lymphoma, colorectal cancer, cutaneous squamous cell carcinoma, diffuse large b cell lymphoma, esophageal cancer, follicular lymphoma, head and neck squamous cell carcinoma, hodgkin lymphoma, hormone receptor positive breast carcinoma, non small cell lung cancer, small bowel cancer, triple negative breast cancer